PROMIS – PRospective study Of MammaPrint in breast cancer patients with an Intermediate recurrence Score

Publication Name: Cancer Research

Author(s): Hatem Soliman, Sarah Untch, Lisette Stork-Sloots

PROMIS is a prospective study that will investigate the additional value of MammaPrint, BluePrint and TargetPrint in women with an intermediate Oncotype DX score. An initial CRF – capturing baseline patient characteristics, pathology information, Oncotype DX score and the recommended … Continued

MINT I – Multi-Institutional Neoadjuvant Therapy, MammaPrint Project I

Publication Name: Cancer Research

Author(s): Charles Cox, Peter Blumencranz, Douglas Reintgen, Ruben Saez, Nicole Howard, Jessica Gibson, Lisette Stork-Sloots, Femke de Snoo, Stefan Glück

Treatment of locally advanced breast cancer (LABC) with neoadjuvant chemotherapy measures the in vivo response to chemotherapy,1 assesses long-term clinical outcomes associated with that response2,3 and enables some patients to undergo breast-conservation therapy due to therapeutic down-staging of the tumor.  In the current study, the … Continued

Comparison of molecular (BluePrint+MammaPrint) and pathological subtypes for breast cancer among the first 800 patients from the EORTC 10041/BIG 3-04 (MINDACT) trial

Publication Name: SABCS 2012 Poster

Author(s): Giuseppe Viale, Leen Slaets, Femke de Snoo, Laura J. van ‘t Veer, Emiel J. Rutgers, Martine Piccart, Jan Bogaerts, Jeroen van den Akker, Lisette Stork-Sloots, Kristel Engelen, Leila Russo, Patrizia Dell’Orto, Fatima Cardoso

Biology has become the main driver of breast cancer therapy. Intrinsic biological subtypes by gene expression profiling have been identified.  Pathology can be used to define surrogates of these subtypes but these are not always concordant, which may lead to … Continued

NBRST – Prospective neo-adjuvant registry trial linking MammaPrint, subtyping and treatment response: Neoadjuvant Breast Registry – Symphony Trial

Publication Name: Cancer Research

Author(s): Pat Whitworth, Mark Gittleman, Stephanie Akbari, Bichlien Nguyen, Paul Baron, Michael Rotkiss, Jennifer Beatty, Jessica Gibson, Lisette Stork-Sloots, Femke de Snoo, Peter Beitsch

The scope of this registry study is to measure chemosensitivity as defined by pCR (primary endpoint), or endocrine sensitivity as defined by partial response (decrease in longest tumor diameter or residual cancer burden category 1 (RCB1), a primary endpoint for … Continued

The PARSC Trial, a Prospective Study for the Assessment of Recurrence Risk in Stage II Colon Cancer Patients Using ColoPrint

Publication Name: ASCO 2011 Poster

Author(s): R. Salazar, R. Rosenberg, M. Lutke Holzik, J. Marshall4 , J. J. M. Van Der Hoeven, B. Glimelius, F. Bibeau, L. Stork-Sloots

Background: An 18-gene expression profile, ColoPrint, has been developed for identifying CC patients more likely to develop recurrent disease and who would be candidates for adjuvant chemotherapy. The gene signature was validated in in-silico datasets and independent patient cohorts of stage … Continued

I-SPY 2 – An adaptive breast cancer trial design in the setting of neoadjuvant chemotherapy

Publication Name: Clinical Pharmacology Therapeutics

Author(s): Barker AD, Sigman CC, Kelloff GJ, Hylton NM, Berry DA, Esserman LJ.

I-SPY 2 (investigation of serial studies to predict your therapeutic response with imaging and molecular analysis 2) is a process targeting the rapid, focused clinical development of paired oncologic therapies and biomarkers. The framework is an adaptive phase II clinical … Continued

Daily clinical practice of fresh tumour tissue freezing and gene expression profiling; logistics pilot study preceding the MINDACT trial.

Publication Name: European Journal of Cancer

Author(s): S. Mook, H. Bonnefoi, G. Pruneric, D. Larsimont, J. Jaskiewicz, M.D. Sabadell, G. MacGrogan, L.J. van’t Veer, F. Cardoso, E.J. Rutgers.

Purpose: The 70-gene prognosis-signature is a prognostic tool for early breast cancer analysis. In addition to scientific evidence, implementation of the signature in clinical trials and daily practice requires logistical feasibility. The aim of our study was to test logistics … Continued

Clinical Application of the 70-Gene Profile: The MINDACT Trial

Publication Name: Journal of Clinical Oncology

Author(s): Cardoso F1, Van't Veer L, Rutgers E, Loi S, Mook S, Piccart-Gebhart MJ

The 70-gene profile is a new prognostic tool that has the potential to greatly improve risk assessment and treatment decision making for early breast cancer. Its prospective validation is currently ongoing through the MINDACT (Microarray in Node-Negative Disease May Avoid … Continued